Drug Development

A new AI-powered blood test from CareDx shows promise in detecting cancer relapse weeks earlier, offering new hope for transplant patients.

Pharming Group projects strong 2026 growth, fueling ambitious clinical programs for rare immunodeficiencies and mitochondrial diseases.

Bolstered by a massive capital infusion and strong investor demand, Vaxcyte is set to accelerate its broad-spectrum vaccine pipeline against market leaders.

Death rates fall, but a new report reveals rising incidence and stark inequities. Can new drugs and AI reshape the future for all patients?

Devonian appoints veteran CFO Dennis Turpin and corrects stock options, signaling a strategic shift as it aims to overcome financial hurdles and advance its pipeline.

A new liquid biopsy more accurately predicts cancer recurrence than standard methods, offering new hope and clarity for patients after surgery.

vTv Therapeutics shores up its finances with a deal worth up to $135M, sharpening its focus on a breakthrough Type 1 diabetes drug, cadisegliatin.

Ensem Therapeutics expands its global trial for ETX-636, a next-gen cancer drug designed to avoid common toxicities, into China's vast patient market.

With a major Phase 3 trial now in Europe, Crystalys Therapeutics aims to fill a critical gap in gout care with a drug already proven in Asian markets.

Mwyngil Therapeutics starts clinical trials for a novel brain-penetrating drug, aiming to tackle neuroinflammation at its source in MS and Parkinson's.

The Spanish biotech firm strengthens its IP for a novel aggression treatment, targeting a growing multi-billion dollar Japanese CNS market.

A life-changing treatment for a rare kidney disease is now easily accessible in France, ending a long wait for patients and bolstering a French pharma firm.

Early clinical results for MP0712, a novel Radio-DARPin, suggest a breakthrough for targeting aggressive cancers like SCLC while sparing healthy tissue.

Shane Kovacs's exit from Olema Oncology introduces leadership questions as the biotech firm nears a pivotal data readout for its lead breast cancer drug.

Tevogen Bio's stock surged on news of a potential special dividend, but a closer look reveals a risky promise from a pre-revenue firm facing major hurdles.

Corcept Therapeutics' stock plummeted and it now faces legal probes after the FDA rejected its key drug, revealing the company was warned not to apply.

Promising Phase 2 data for a potential first-in-class neuropathic corneal pain therapy to be showcased, offering new hope for a debilitating condition.

As its promising prostate cancer drug nears Phase 3, Convergent Therapeutics hires a new CPO to build the team for its next critical growth phase.

Over 60% of cats and 59% of dogs are overweight, a silent crisis shortening lives. Vets warn against risky shortcuts and urge proactive, guided care.

Profusa launches its Lumee system for research, aiming to capture a piece of the $47B CRO market and revolutionize drug development with real-time data.